Overview

This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions

Status:
Withdrawn
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study will be the first study investigating the safety, pharmacokinetics (PK), and efficacy of SBS-101 on oral pre-malignant lesions. As such, no clinical data has yet been generated using SBS-101 oral adhesive film.
Phase:
Phase 1
Details
Lead Sponsor:
Skyline Biosciences